Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy.
Information source: University of Colorado, Denver
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Adrenal Suppression
Intervention: Prevalence study only, no study intervention (Other)
Phase: N/A
Status: Completed
Sponsored by: University of Colorado, Denver Official(s) and/or principal investigator(s): Monique A Spillman, MD, Principal Investigator, Affiliation: University of Colorado Denver Anschutz Medical Center
Summary
Gynecologic Oncology patients have several different chemotherapy regimens, and
dexamethasone is now routinely given to prevent allergic reactions to the chemotherapeutic
agents. The most common chemotherapeutic agents used are paclitaxel and carboplatin. This
combination regimen is given every three weeks for a total of 5-6 doses. Each dose is given
after administration of 20 mg dexamethasone twelve hours prior to and the morning of
chemotherapy. Dexamethasone is used for its antiemetic effects, but also to minimize the
potentially fatal hypersensitivity reaction that can occur with paclitaxel. Another
commonly used chemotherapy regimens is weekly cisplatin given with one dose of dexamethasone
for cervical cancer. Chronic steroids are known to cause adrenal suppression, but it is not
known if the amount of dexamethasone given with the gynecologic cancer chemotherapy
regimens described above causes adrenal insufficiency in these patients.
The investigators hypothesis is that some women receiving steroids with their chemotherapy
may have adrenal insufficiency, and that they will have greater than normal
chemotherapy-related fatigue.
Clinical Details
Official title: A Prevalence Study of Adrenal Suppression After Adjuvant Corticosteroid Administration During Gynecologic Cancer Chemotherapy
Study design: Observational Model: Cohort, Time Perspective: Prospective
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
1. Patients must have age greater or equal to 18
2. Patients with histologic diagnosis of cervical, endometrial, or ovarian cancer who
are receiving chemotherapy
3. Any clinical stage allowed
4. GOG performance status 0, 1, or 2
5. Written informed consent and HIPAA authorization obtained prior to any initiation of
study procedures
Exclusion Criteria:
1. The presence of other comorbid conditions known to impact adrenal function, whether
primary adrenal dysfunction, or dysfunction due to administration of steroids for
treatment (Addison's or Cushings disease, pituitary or hypothalamic disease, systemic
lupus erythematosis, rheumatoid arthritis, asthma)
2. Patients who have received chronic or pulsed steroids within the past 9 months.
3. Patients with previous diagnosis of adrenal suppression.
4. Underlying psychiatric condition which would, in the opinion of the investigator,
preclude compliance with study requirements
5. Women who are pregnant are not eligible to participate.
6. Patients who have received prior radiotherapy or chemotherapy for an abdominal or
pelvic tumor are excluded. Prior radiation or adjuvant chemotherapy for localized
cancer of the breast, head and neck, or skin is permitted, provided that it was
completed more than 3 years prior to registration, and the patient remains free of
recurrent or metastatic disease.
7. Patients with invasive malignancies, with exception of non-melanoma skin cancer, and
specific malignancies noted above, who had (or have) any evidence of other cancer
present within the last 5 years or whose previous cancer treatment contraindicates
this protocol are excluded.
Locations and Contacts
University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado 80045, United States
Additional Information
Starting date: September 2010
Last updated: August 6, 2015
|